#Singapore #cancer therapy #NUS #Gold Nanoparticles

Revolutionizing Cancer Treatment with Gold Nanoparticles

In a groundbreaking development, researchers from the National University of Singapore (NUS) have introduced a revolutionary high-throughput platform that dramatically enhances the precision of cancer therapies. This new system focuses on the use of gold nanoparticles, which are designed to deliver therapeutic agents directly to mitochondria—the energy centers crucial to cancer cell metabolism. By tagging these nanoparticles with unique DNA barcodes, the team has made it possible to identify and track their effectiveness in real time within living tumor models.

The Science Behind the Breakthrough

Mitochondria play a pivotal role in regulating essential cellular processes, including energy production and programmed cell death. This makes them attractive targets for cancer therapy, as directly delivering drugs to these organelles can disrupt tumor metabolism and initiate cancer cell death. However, this task is far from straightforward. Nanoparticles must successfully navigate various biological barriers: traveling through the bloodstream, entering tumor cells, and avoiding degradation from cellular compartments before reaching their intended destination.

To tackle this challenge, Assistant Professor Andy Tay, leading the research, emphasizes the complexity of the process: "Getting nanoparticles to the right place inside the body involves putting them through a complicated obstacle course." By employing DNA barcodes, the team can track dozens of nanoparticle designs at once, significantly speeding up the identification of those most capable of overcoming these obstacles.

A Closer Look at the Research

In their study, published in Advanced Materials, the NUS team created a library of 30 unique gold nanoparticle formulations, each varying in shape, size, and targeting ligands. After administering these designs to preclinical tumor models, they utilized next-generation sequencing to analyze the distribution of each variant. This innovative multiplexing approach generated over 1,000 pieces of in vivo data while utilizing approximately 30% fewer models than conventional screening methods used previously.

Among the tested nanoparticle formulations, two emerged as particularly promising. One was a folic acid-modified cubic gold nanoparticle that demonstrated an astonishing 99% reduction in tumor size during preclinical tests when combined with a targeted RNA therapy and mild photothermal treatment. The other was a large spherical particle that benefitted from a protective protein layer, improving its circulation and accumulation within tumor cells.

Implications for Precision Medicine

These findings suggest a shift towards precision nanomedicine, which could greatly enhance the efficiency of cancer treatments. The research illustrates that the design of nanoparticles is influenced by a combination of factors rather than a single characteristic. According to Asst Prof Tay, "High-throughput screening platforms like ours allow us to uncover these relationships, moving beyond a trial-and-error approach to nanoparticle design."

As the team aims to expand the nanoparticle library further, they are also integrating artificial intelligence tools to process the vast amount of data generated. The intention is to adapt this technology for targeting other cellular organelles and to refine the delivery of drugs for numerous diseases.

In conclusion, this innovative method of using DNA barcodes not only opens new pathways for effective cancer treatments but also sets the stage for potentially groundbreaking advancements in the field of nanomedicine. The ongoing research could lead to more precise and effective therapies, significantly reshaping our approach to combatting cancer.

For further information, visit NUS News.